ReviewFrontiers in immunology2026
Immune-microbe interactions in pediatric ulcerative colitis: clinical features, pathogenesis, and novel targeted therapeutic strategies.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric ulcerative colitis (PUC) is a chronic, immune-mediated inflammatory disease that exhibits different clinical characteristics and pathogenesis from those in adults. PUC is more severe and has a wider lesion range. The main manifestations include diarrhea, bloody stool, abdominal pain, and tenesmus, as well as systemic symptoms such as weight loss and anemia. However, the current treatment regimens for children with PUC cannot meet the increasing clinical cure demands, which is due to insufficient understanding of the pathogenesis of PUC. The pathogenesis of PUC is believed to be caused by the interaction of genetic and environmental factors, leading to an excessive and dysregulated immune response of the intestinal mucosa to microorganisms. This review summarizes the epithelial barrier defect, excessive innate immune activation, adaptive immune dysregulation, and associated cytokine dysregulation in the pathogenesis of PUC. Moreover, the potential therapeutic effects of new immunomodulatory therapies, including microbial therapy and anti-integrin biological agents, on PUC are summarized. The aim is to deepen the understanding of the pathogenesis and treatment mode that distinguish PUC from adults and promote precise treatment for PUC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.